One CRISPR injection, a permanent effect: when gene therapy becomes economics
87% reduction in attacks with a single dose. Phase 3 results from Intellia Therapeutics mark the advent of CRISPR in vivo, the first gene therapy that edits DNA directly inside the human body. No more need to extract patient cells, modify them in the laboratory, and reinject them — a simple injection suffices.
This technical breakthrough transforms the economic equation of genetic medicine. Gone are the hospital protocols spanning several weeks costing two million dollars per patient. But this technological leap poses an unprecedented question: how do you finance a permanent treatment that is paid for upfront in insurance systems designed to reimburse monthly?
The essentials
- Intellia’s CRISPR treatment reduced the frequency of hereditary angioedema attacks by 87% with a single injection in 80 patients
- This in vivo therapy will cost approximately $200,000 compared to $2 million for current ex vivo treatments
- Hereditary angioedema affects one person per 50,000 worldwide, meaning 160,000 potential patients
- Intellia plans a regulatory filing by late 2026 for commercialization in 2027-2028
CRISPR crosses the threshold of the human body
Intellia Therapeutics’ HAELO-3 phase 3 trial has just proven that genes can be edited directly in the living organism. In 80 patients with hereditary angioedema, a single injection of the NEXIGURAN treatment reduced the monthly frequency of attacks by 87% compared to placebo. Even more impressive: 89% of treated patients experienced zero attacks requiring medical intervention during the six-month follow-up period.
This performance rests on a major technical innovation. Unlike current CRISPR therapies that require extracting patient cells, modifying them in the laboratory, then reinjecting them, NEXIGURAN uses lipid nanoparticles to deliver gene-editing tools directly to the liver. Once there, CRISPR precisely cuts the KLKB1 gene that produces kallikrein, the protein responsible for inflammatory attacks.
“We are literally editing genes inside the human body,” explains John Leonard, Intellia’s chief medical officer. Hereditary angioedema causes sudden swelling of the face, throat, and extremities that can be fatal. Without treatment, 25% of patients die from asphyxia.
Ten times cheaper than extracting cells
This technical revolution transforms the economic equation. Current gene therapies like Novartis’s Zolgensma cost $2.1 million per dose. They require heavy hospital infrastructure: cell extraction, modification in a P3 laboratory, cell culture, reinjection under intensive medical supervision.
NEXIGURAN is administered as an intravenous injection in 15 minutes at a standard infusion center. Intellia estimates the price between $150,000 and $200,000 per patient — ten times less than ex vivo therapies. “Hospital logistics represent 60% of the costs of cell therapies,” clarifies Andrew Adams, analyst at Stifel. “CRISPR in vivo completely changes the game.”
This drastic cost reduction opens the market to more common diseases. Hereditary angioedema affects only one person per 50,000, meaning approximately 160,000 patients worldwide. But Intellia is already developing similar treatments for hemophilia A and B, which affect 400,000 people, or hereditary cardiomyopathy, which affects 700,000 patients.
The challenge for insurance systems facing permanence
Medical innovation creates its own inequalities. A treatment that works in one injection poses an unprecedented economic problem for insurance systems designed to reimburse monthly care. Medicare and American private insurers calculate their provisions based on predictable annual costs, not single payments of $200,000.
“It’s a paradigm shift,” acknowledges David Feinberg, former head of Google Health. “How can an insurer collecting $500 in monthly premiums advance $200,000 all at once?” The British NHS healthcare system already refused to reimburse Zolgensma, deeming the initial cost too high despite its proven efficacy.
Laboratories are developing innovative financing models. Bluebird Bio offers reimbursement spread over five years for its gene therapies. Intellia is studying “pay-for-performance” contracts where the insurer only pays if the patient remains in remission. “We need to reinvent medical financing,” admits John Leonard.
This economy of permanence risks creating a two-tiered medicine. Affluent patients will pay cash to access curative treatments immediately. Others will depend on the goodwill of insurers and price negotiations that can take years. Therapeutic innovation amplifies the inequalities it claims to solve.
The global race toward commercial gene editing
Europe and Asia are not falling behind. CRISPR Therapeutics, based in Switzerland, is developing CTX001 to treat sickle cell disease directly in vivo. The company obtained $420 million from Vertex Pharmaceuticals to accelerate its clinical trials. First treatment expected in 2028.
China is betting on BGI Genomics and its Shenzhen laboratories to compete with Americans. Beijing Genomics Institute announced 800 million yuan investment in gene editing. The objective: offer CRISPR therapies at $50,000 per patient by first targeting common genetic diseases in Asia such as thalassemia, which affects 280 million people.
This global competition is transforming biomedical research. Unlike traditional drugs requiring decades of development, CRISPR allows precise targeting of any identified genetic sequence. “We are moving from artisanal chemistry to industrial genetic engineering,” summarizes Jennifer Doudna, co-inventor of CRISPR and 2020 Nobel Prize winner in Chemistry.
Investments are following. The gene editing sector raised $12.4 billion in 2025 according to GlobalData, with 60% for in vivo therapies. Prime Medicine, Beam Therapeutics, and Base Editing Inc. are each developing around twenty treatments in the pipeline. The objective: transform CRISPR from a laboratory tool into a mass-market medicine.
Regulating the irreversible
Permanent gene editing poses unprecedented regulatory challenges. How do you test the safety of a permanent treatment? European and American health agencies require monitoring patients for a minimum of 15 years to detect any late-stage side effects. “We are editing the fundamental genetic instruction,” reminds Peter Marks, director of the FDA’s Center for Biology. “Caution is warranted.”
Ethical debates are intensifying. Should preventive gene editing be authorized in healthy individuals carrying risk mutations? CRISPR can suppress the APOE4 gene that multiplies Alzheimer’s risk by 12, but also benign genetic variants. “We risk standardizing the human genome,” worries Marcy Darnovsky, director of the Center for Genetics and Society.
Accessibility remains the main challenge. The World Health Organization estimates that 400 million people suffer from rare genetic diseases worldwide, with 80% living in low or middle-income countries. Even at $50,000 per treatment, CRISPR will remain inaccessible for the majority. Laboratories are exploring partnerships with governments to finance access in emerging countries, but economic models remain unclear.
Definitive medicine as new standard
This transition toward unique curative treatments is transforming the pharmaceutical industry. No more need to build patient loyalty with chronic medications — the objective becomes curing once and for all. “We are moving from a subscription model to a transactional model,” analyzes Kevin Gorman, former head of Neurocrine Biosciences.
This evolution is disrupting research and development. Rather than optimizing molecules for 20 years of daily intake, laboratories are designing one-off genetic interventions. Intellia is investing $400 million in an automated platform capable of developing 50 CRISPR therapies in parallel. Industrialization is replacing medical craftsmanship.
Patients will have to adapt to this new reality. No more daily pills, but permanent medical decisions. No more chronic disease management, but targeted cures that transform the patient’s very identity. This definitive medicine promises the eradication of thousands of genetic pathologies over the next two decades. It remains to invent the economic and ethical systems to democratize these advances beyond the elites who can afford them.
Sources
- STAT News - Intellia CRISPR phase 3 trial results for hereditary angioedema
- GlobalData - Gene editing market analysis 2025
- FDA Center for Biologics Evaluation and Research guidelines
- World Health Organization - Report on rare genetic diseases 2025